Document Detail

Sorafenib-Induced Hepatocellular Carcinoma Cell Death Depends on Reactive Oxygen Species Production in vitro and in vivo.
MedLine Citation:
PMID:  22902857     Owner:  NLM     Status:  Publisher    
Sorafenib is presently the only effective therapy in advanced Hepatocellular carcinoma (HCC). Since most anticancer drugs act, at least in part, through the generation of reactive oxygen species, we investigated whether sorafenib can induce an oxidative stress. The effects of sorafenib on intracellular ROS production and cell death were assessed in vitro in human (HepG2) and murine (Hepa 1.6) HCC cell lines and human endothelial cells (HUVEC) as controls. In addition, twenty-six sera from HCC patients treated by sorafenib were analyzed for serum levels of advanced oxidation protein products (AOPP). Sorafenib significantly and dose-dependently enhanced in vitro ROS production by HCC cells. The SOD mimic MnTBAP decreased sorafenib-induced lysis of HepG2 cells by 20% and of Hepa 1.6 cells by 75% compared to HCC cells treated with 5mg/l sorafenib alone. MnTBAP significantly enhanced by 25% tumor growth in mice treated by sorafenib. On the other hand, serum levels of AOPP were higher in HCC patients treated by sorafenib than in sera collected before treatment (P less than 0.001). An increase in serum AOPP concentration greater than or equal to 2 muM chloramine T equivalent after 15 days of treatment is a predictive factor for sorafenib response with higher progression free survival (p less than 0.05) and overall survival rates (p less than 0.05). As a conclusion, sorafenib dose-dependently induces the generation of ROS in tumor cells in vitro and in vivo. The sera of Sorafenib-treated HCC patients contain increased AOPP levels that are correlated with the clinical effectiveness of sorafenib and can be used as a marker of effectiveness of the drug.
Romain Coriat; Carole Nicco; Christiane Chereau; Olivier Mir; Jerome Alexandre; Stanislas Ropert; Bernard Weill; Stanislas Chaussade; Francois Goldwasser; Frederic Batteux
Related Documents :
21369697 - Lithium reduces tumorigenic potential in response to egf signaling in human colorectal ...
2670727 - T cells in follicular centroblastic/centrocytic (cleaved follicular centre cell) lympho...
22367497 - Zinc induces caspase-dependent mitochondrial pathway of the programmed cell death in ha...
22341977 - Overexpression of reptin in renal cell carcinoma contributes to tumor malignancies and ...
16889367 - Construction of a cultivation system of a yeast single cell in a cell chip microchamber.
16346267 - Ability of daphnia cell-free extract to damage escherichia coli cells.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-8-17
Journal Detail:
Title:  Molecular cancer therapeutics     Volume:  -     ISSN:  1538-8514     ISO Abbreviation:  Mol. Cancer Ther.     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-8-20     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101132535     Medline TA:  Mol Cancer Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
1Laboratoire d'immunologie, EA 1833, Universite Paris Descartes, Faculte de Medecine, Hopital Cochin.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The Impacted Ureteral Stone.
Next Document:  Involvement of hypothalamic cyclooxygenase-2, interleukin-1? and melanocortin in the development of ...